Plozasiran Reduces Triglyceride Levels in Mixed Hyperlipidemia
By Elana Gotkine HealthDay Reporter
MONDAY, June 3, 2024 -- For individuals with mixed hyperlipidemia, plozasiran reduces triglyceride levels at 24 weeks, according to a study published online May 28 in the New England Journal of Medicine.
Christie M. Ballantyne, M.D., from the Baylor College of Medicine and Texas Heart Institute in Houston, and colleagues conducted a 48-week, randomized trial assessing the safety and efficacy of plozasiran in 353 patients with mixed hyperlipidemia. Within each of four cohorts, participants were assigned to receive plozasiran or placebo in a 3:1 ratio. In the first three cohorts, participants received 10-, 25-, or 50-mg subcutaneous injections of plozasiran or placebo on day 1 and week 12 (quarterly dose), while participants received 50 mg plozasiran or placebo on day 1 and week 24 (half-yearly dose) in the fourth cohort.
The researchers identified significant reductions in the fasting triglyceride level with plozasiran at week 24, with differences in the least-squares mean percent change from baseline of −49.8, −56.0, −62.4, and −44.2 percentage points with the 10-mg, 25-mg, and 50-mg quarterly doses and the 50-mg half-yearly dose, respectively, compared with placebo. Ten percent of those receiving placebo had worsening glycemic control, as did 12, 7, 20, and 21 percent of those receiving the 10-, 25-, and 50-mg quarterly doses and the 50-mg half-yearly dose, respectively.
"This trial has helped in laying the groundwork for a more extensive outcomes trial, which would more rigorously test whether plozasiran reduces levels of non-high-density lipoprotein cholesterol and cholesterol remnants and the risk of atherosclerotic cardiovascular disease," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Arrowhead, which manufactures plozasiran and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C
FRIDAY, March 28, 2025 -- Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin...
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
FRIDAY, Feb. 21, 2025 -- Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.